Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SNS-101 |
| Synonyms | |
| Therapy Description |
SNS-101 is a monoclonal antibody that targets VSIR (VISTA; PD1H), which may lead to increase in tumor-infiltrating T-cells and enhanced antitumor immune response (Journal for ImmunoTherapy of Cancer 2022;10). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SNS-101 | SNS101|SNS 101 | VSIR Antibody 6 | SNS-101 is a monoclonal antibody that targets VSIR (VISTA; PD1H), which may lead to increase in tumor-infiltrating T-cells and enhanced antitumor immune response (Journal for ImmunoTherapy of Cancer 2022;10). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05864144 | Phase Ib/II | Cemiplimab + SNS-101 SNS-101 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |